# US 2014/0194527 A1 · Geranylgeranylacetone formulations and retinal delivery thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0194527 A1
- Document ID: US20140194527A1
- Status: Published application
- Kind: A1
- Application number: 13/943,606
- Filed: 2013-07-16
- Published: 2014-07-10
- Earliest claimed: 2012-02-29
- Assignees: Rohto USA, Inc.
- Inventors: Hiroaki Serizawa
- Web page: https://patentgrep.com/patent/US20140194527A1

## CPC

- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/121: acyclic
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein is a pharmaceutical formulation comprising at least one geranylgeranyl acetone in the form of an eye drop. Also provided herein are methods of treating neural diseases or disorders by administering such pharmaceutical formulations.

## Claims

### Claim at position 1

1-42. (canceled)

### Claim 43

A method of delivering geranylgeranyl acetone (GGA) into a retina of a subject, the method comprising administering topically on an ocular surface of the subject a composition comprising geranylgeranyl acetone (GGA).

### Claim 44

A method of treating a retinal disease in a subject, the method comprising administering topically on an ocular surface of the subject a composition comprising geranylgeranyl acetone (GGA).

### Claim 45

A method of inhibiting a retinal optical nerve damage in a subject, the method comprising administering topically on an ocular surface of the subject a composition comprising geranylgeranyl acetone (GGA).

### Claim 46

(canceled)

### Claim 47 (depends on 43)

The method according to claim 43, wherein the GGA is trans isomer free of cis isomer or a mixture of cis and trans isomers.

### Claim 48 (depends on 43)

The method according to claim 43, wherein the composition comprises 0.0001-10 wt % of GGA.

### Claim 49 (depends on 43)

The method according to claim 43, wherein the composition is an eye drop.

### Claim 50 (depends on 44)

The method according to claim 44, wherein the GGA is trans isomer free of cis isomer or a mixture of cis and trans isomers.

### Claim 51 (depends on 44)

The method according to claim 44, wherein the composition comprises 0.0001-10 wt % of GGA.

### Claim 52 (depends on 44)

The method according to claim 44, wherein the retinal disease derives from or is related to glaucoma, macular degeneration, exposure to UV light, trauma, stroke, optic neuritis, ischemia, infection, compression from a tumor, compression from an aneurysm or Leber's hereditary optic neuropathy.

### Claim 53 (depends on 44)

The method according to claim 44, which further comprises increasing intraocular levels of HSP 70, thereby treating the retinal disease.

### Claim 54 (depends on 44)

The method according to claim 44, wherein the composition is an eye drop.

### Claim 55 (depends on 45)

The method according to claim 45, wherein the GGA is trans isomer free of cis isomer or a mixture of cis and trans isomers.

### Claim 56 (depends on 45)

The method according to claim 45, wherein the composition comprises 0.0001-10 wt % of GGA.

### Claim 57 (depends on 45)

The method according to claim 45, wherein the retinal optical nerve damage derives from or is related to glaucoma, macular degeneration, exposure to UV light, trauma, stroke, optic neuritis, ischemia, infection, compression from a tumor, compression from an aneurysm or Leber's hereditary optic neuropathy.

### Claim 58 (depends on 45)

The method according to claim 45, which further comprises increasing intraocular levels of HSP 70, thereby inhibiting retinal optical nerve damage.

### Claim 59 (depends on 45)

The method according to claim 45, wherein the composition is an eye drop.